Key facts
- This page summarizes ORBIMED ADVISORS LLC's Form 4 filing for Prelude Therapeutics Inc (PRLD).
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 23 Apr 2026, 18:48.
ORBIMED ADVISORS LLC - 21 Apr 2026 Form 4 Insider Report for Prelude Therapeutics Inc (PRLD)
- Reporting relationship
- Director, 10%+ Owner
- Issuer ticker
- PRLD
- Reported as of
- 21 Apr 2026
- Net transaction value
- +$12,499,999
- SEC form
- 4
- Accepted by SEC
- 23 Apr 2026, 18:48:25 UTC
- Prior SEC filing
- 21 Apr 2026
- Next SEC filing
- 11 May 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Carl L. Gordon, Member of OrbiMed Advisors LLC
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
ORBIMED ADVISORS LLC filed Form 4 for Prelude Therapeutics Inc (PRLD) on 23 Apr 2026.
Change
- Previous filing in this sequence was filed on 21 Apr 2026.
- Current net transaction value: +$12,499,999.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (4)
CIK 0001055951
Primary reporting owner
ORBIMED ADVISORS LLC
- Relationship
- Director, 10%+ Owner
- Address
- 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK
- Signature
- /s/ Carl L. Gordon, Member of OrbiMed Advisors LLC
- Signature date
- 23 Apr 2026
CIK 0001682115
OrbiMed Capital GP VI LLC
- Relationship
- Director, 10%+ Owner
- Address
- 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK
- Signature
- /s/ Carl L. Gordon, Member of OrbiMed Capital GP VI LLC
- Signature date
- 23 Apr 2026
CIK 0001157524
ORBIMED CAPITAL LLC
- Relationship
- Director, 10%+ Owner
- Address
- 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK
- Signature
- /s/ Carl L. Gordon, Member of OrbiMed Capital LLC
- Signature date
- 23 Apr 2026
CIK 0001808744
OrbiMed Genesis GP LLC
- Relationship
- Director, 10%+ Owner
- Address
- 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK
- Signature
- /s/ Carl L. Gordon, Member of OrbiMed Genesis GP LLC
- Signature date
- 23 Apr 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
PRLD
transaction
Common Stock
Purchase
- Transaction value
- $7,499,999
- Shares
- +1,689,189
- Change %
- +17%
- Price
- $4.44
- Shares after
- 11,808,945
- Date
- 21 Apr 2026
- Ownership
- See footnotes
- Footnotes
- F1, F2, F5
PRLD
transaction
Common Stock
Purchase
- Transaction value
- $7,499,999
- Shares
- +1,689,189
- Change %
- +17%
- Price
- $4.44
- Shares after
- 11,808,945
- Date
- 21 Apr 2026
- Ownership
- See footnotes
- Footnotes
- F1, F2, F5
PRLD
transaction
Common Stock
Purchase
- Transaction value
- $7,499,999
- Shares
- +1,689,189
- Change %
- +17%
- Price
- $4.44
- Shares after
- 11,808,945
- Date
- 21 Apr 2026
- Ownership
- See footnotes
- Footnotes
- F1, F2, F5
PRLD
transaction
Common Stock
Purchase
- Transaction value
- $7,499,999
- Shares
- +1,689,189
- Change %
- +17%
- Price
- $4.44
- Shares after
- 11,808,945
- Date
- 21 Apr 2026
- Ownership
- See footnotes
- Footnotes
- F1, F2, F5
PRLD
transaction
Common Stock
Purchase
- Transaction value
- $4,999,999
- Shares
- +1,126,126
- Change %
- Price
- $4.44
- Shares after
- 1,126,126
- Date
- 21 Apr 2026
- Ownership
- See footnotes
- Footnotes
- F1, F4, F5
PRLD
transaction
Common Stock
Purchase
- Transaction value
- $4,999,999
- Shares
- +1,126,126
- Change %
- Price
- $4.44
- Shares after
- 1,126,126
- Date
- 21 Apr 2026
- Ownership
- See footnotes
- Footnotes
- F1, F4, F5
PRLD
transaction
Common Stock
Purchase
- Transaction value
- $4,999,999
- Shares
- +1,126,126
- Change %
- Price
- $4.44
- Shares after
- 1,126,126
- Date
- 21 Apr 2026
- Ownership
- See footnotes
- Footnotes
- F1, F4, F5
PRLD
transaction
Common Stock
Purchase
- Transaction value
- $4,999,999
- Shares
- +1,126,126
- Change %
- Price
- $4.44
- Shares after
- 1,126,126
- Date
- 21 Apr 2026
- Ownership
- See footnotes
- Footnotes
- F1, F4, F5
PRLD
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 526,300
- Date
- 21 Apr 2026
- Ownership
- See footnotes
- Footnotes
- F3, F5
PRLD
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 526,300
- Date
- 21 Apr 2026
- Ownership
- See footnotes
- Footnotes
- F3, F5
PRLD
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 526,300
- Date
- 21 Apr 2026
- Ownership
- See footnotes
- Footnotes
- F3, F5
PRLD
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 526,300
- Date
- 21 Apr 2026
- Ownership
- See footnotes
- Footnotes
- F3, F5
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 5 footnotes
Footnote F1
These securities were purchased in an underwritten public offering.
Footnote F2
These securities are held of record by OrbiMed Private Investments VI, LP ("OPI VI"). OrbiMed Capital GP VI LLC ("GP VI") is the general partner of OPI VI and OrbiMed Advisors LLC ("OrbiMed Advisors") is the managing member of GP VI. By virtue of such relationships, OrbiMed Advisors and GP VI may be deemed to have voting power and investment power over the securities held by OPI VI and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the securities held by OPI VI.
Footnote F3
These securities are held of record by OrbiMed Partners Master Fund Limited ("OPM"). OrbiMed Capital LLC ("OrbiMed Capital") is the investment advisor to OPM. OrbiMed Capital is a relying advisor of OrbiMed Advisors. OrbiMed Advisors and OrbiMed Capital exercise voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPM.
Footnote F4
These securities are held of record by OrbiMed Genesis Master Fund, L.P. ("Genesis Master Fund"). OrbiMed Genesis GP LLC ("Genesis GP") is the general partner of Genesis Master Fund. OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by Genesis Master Fund. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by Genesis Master Fund.
Footnote F5
This report on Form 4 is filed by OrbiMed Advisors, GP VI, OrbiMed Capital and Genesis GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors and GP VI have designated a representative, David Bonita, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report on Form 4 shall not be deemed an admission that any such person or entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.